<div id="readability-page-1">Shares of Viatris (VTRS) traded higher on Monday after UBS upgraded the company to Buy from Neutral and lifted its price target to $11 from $8 per share, citing a promising growth outlook and a growing pipeline of drugs. Analyst Ashwani Verma hiked his estimates for the company, noting, “We layer in new product cycle pipeline &amp; maintain potential c...</div>

美國制藥 ETF - iShares

IBBQ

基因改革 ETF - ARK

醫療業 ETF - SPDR

醫療業 ETF - Vanguard

標普全球醫療股指數 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

暉致

<p>在瑞銀將 Viatris (VTRS) 的股票評級從中性上調至買入後，該股上漲，目標價從每股 8 美元提高至 11 美元。分析師 Ashwani Verma 強調了積極的增長前景和強大的藥物管線，並相應調整了預期。他指出，Viatris 的估值相對於 2027 年的共識每股收益預期為 5 倍，具有吸引力。總體而言，華爾街對 Viatris 持樂觀態度，平均分析師評級為買入，而 Seeking Alpha 則將其評級為持有</p>

Viatris gains as UBS upgrades to buy on outlook and pipeline

Invesco Nasdaq Biotechnology ETF

由於瑞銀基於前景和產品線將評級上調至買入，暉致股價上漲